Fmr LLC Immuneering Corp Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Immuneering Corp stock. As of the latest transaction made, Fmr LLC holds 6,743 shares of IMRX stock, worth $16,318. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,743

Previous 233,198 97.11%

Holding current value

$16,318

Previous $673,000 98.81%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.28 - $2.75 $289,862 - $622,751	-226,455 Reduced 97.11%	6,743 $8,000
Q1 2024 May 13, 2024	SELL	$1.91 - $7.32 $489,435 - $1.88 Million	-256,249 Reduced 52.35%	233,198 $673,000
Q4 2023 Feb 13, 2024	SELL	$4.84 - $8.44 $593,969 - $1.04 Million	-122,721 Reduced 20.05%	489,447 $3.6 Million
Q3 2023 Nov 13, 2023	SELL	$7.21 - $10.68 $333,649 - $494,227	-46,276 Reduced 7.03%	612,168 $4.7 Million
Q2 2023 Aug 11, 2023	BUY	$6.49 - $13.36 $1.66 Million - $3.42 Million	255,923 Added 63.58%	658,444 $6.68 Million
Q1 2023 May 11, 2023	BUY	$3.78 - $10.38 $942,951 - $2.59 Million	249,458 Added 162.98%	402,521 $3.91 Million
Q4 2022 Feb 13, 2023	SELL	$4.09 - $15.0 $286,099 - $1.05 Million	-69,951 Reduced 31.37%	153,063 $742,000
Q3 2022 Nov 10, 2022	SELL	$5.0 - $14.32 $700 - $2,004	-140 Reduced 0.06%	223,014 $3.19 Million
Q2 2022 Aug 12, 2022	BUY	$3.89 - $7.81 $37,468 - $75,225	9,632 Added 4.51%	223,154 $1.21 Million
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $852,862 - $2.24 Million	131,818 Added 161.34%	213,522 $1.38 Million
Q4 2021 Feb 14, 2022	SELL	$16.12 - $31.02 $2.71 Million - $5.22 Million	-168,296 Reduced 67.32%	81,704 $1.32 Million
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $4.25 Million - $8.21 Million	250,000 New	250,000 $6.64 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

9.65M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $63.9M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account